| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDC42 |
| Uniprot No | P60953 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188aa |
| 氨基酸序列 | MQTIKCVVVG DGAVGKTCLL ISYTTNKFPS EYVPTVFDNY AVTVMIGGEP YTLGLFDTAG QEDYDRLRPL SYPQTDVFLV CFSVVSPSSF ENVKEKWVPE ITHHCPKTPF LLVGTQIDLR DDPSTIEKLA KNKQKPITPE TAEKLARDLK AVKYVECSAL TQKGLKNVFD EAILAALEPP EPKKSRRC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CDC42重组蛋白相关的参考文献示例(内容基于公开研究整理，非真实文献)：
---
1. **文献名称**: "Expression and purification of recombinant human CDC42 GTPase in Escherichia coli"
**作者**: Smith J, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达和纯化重组人源CDC42蛋白的优化方法，通过GST标签亲和层析和凝血酶切割获得高纯度蛋白，并验证其GTP结合活性及与下游效应分子PAK1的互作能力。
---
2. **文献名称**: "Structural analysis of CDC42-effector interactions using recombinant protein complexes"
**作者**: Johnson R, et al.
**摘要**: 利用X射线晶体学解析了重组CDC42蛋白与其效应因子WASP的复合物结构，揭示了CDC42的Switch II区域在结合中的关键作用，为设计靶向CDC42信号通路的抑制剂提供结构基础。
---
3. **文献名称**: "Functional characterization of a constitutively active CDC42 mutant in cell migration assays"
**作者**: Lee S, et al.
**摘要**: 通过构建组成性激活突变体(Q61L)的重组CDC42蛋白，在体外细胞迁移模型中证明其显著增强细胞伪足形成和运动能力，并利用荧光共振能量转移(FRET)技术实时监测其激活动力学。
---
注：以上文献为示例，实际引用时需根据具体研究内容检索真实文献(可通过PubMed或Sci-Hub获取原文)。
**Background of CDC42 Recombinant Protein**
CDC42 (Cell Division Cycle 42) is a small GTPase belonging to the Rho family, playing a pivotal role in regulating intracellular signaling networks that govern cell polarity, cytoskeletal reorganization, cell cycle progression, and membrane trafficking. As a molecular switch, CDC42 cycles between an active GTP-bound state and an inactive GDP-bound state, interacting with effector proteins to orchestrate diverse cellular processes, including cell migration, differentiation, and immune responses. Its dysfunction has been linked to various diseases, such as cancer, neurodegenerative disorders, and developmental abnormalities.
Recombinant CDC42 proteins are engineered in vitro using expression systems like *E. coli* or mammalian cells, enabling precise study of its structure and function. These proteins are typically purified via affinity chromatography and validated for activity using GTP-binding assays or interaction studies with downstream effectors (e.g., PAK1 or WASP). Tagged versions (e.g., His-, GST-, or FLAG-tags) facilitate detection, pull-down assays, or structural analysis via techniques like X-ray crystallography or NMR.
Research applications of recombinant CDC42 include dissecting signaling pathways, screening for inhibitors or activators in drug discovery, and modeling disease mechanisms. For instance, studies using recombinant CDC42 have elucidated its role in cancer cell invasion by activating matrix metalloproteinases or in neuronal development by guiding axon guidance. Additionally, engineered mutants (e.g., constitutively active Q61L or dominant-negative T17N) are widely used to manipulate CDC42 activity in cellular and animal models.
Overall, CDC42 recombinant proteins serve as essential tools for advancing fundamental and translational research, bridging molecular insights to therapeutic innovations.
×
